NAD+ (nicotinamide adenine dinucleotide) is one of the most-hyped molecules in longevity research — and one of the few with a genuinely robust scientific foundation. Understanding the biology clearly helps separate what’s established from what’s extrapolated. This is a research-graded breakdown. This overview specifically addresses nad+ biology and aging, and related research is indexed on PubMed.
Why NAD+ Matters Biologically
NAD+ is a coenzyme present in every cell, essential for:
- Energy metabolism: Central to glycolysis, the TCA cycle, and the electron transport chain. Without NAD+, cells cannot produce ATP efficiently.
- Sirtuin activation: Sirtuins (SIRT1-7) are NAD+-dependent deacylases that regulate gene expression, DNA repair, stress response, and metabolic adaptation. They cannot function without NAD+.
- PARP enzymes: Poly(ADP-ribose) polymerases use NAD+ as a substrate for DNA damage repair. Chronic DNA damage (as occurs with aging) depletes NAD+ via PARP activity.
- CD38: An NAD+ hydrolase that increases with inflammation and aging — a major driver of age-related NAD+ decline.
NAD+ levels decline with age in multiple tissues — this is well-established in both rodents and humans. The decline is real. Whether supplementing precursors reverses meaningful downstream effects is the contested question.
NMN vs NR: The Precursor Debate
Both NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors to NAD+ via the salvage pathway:
NR → NMN → NAD+ (via NMNAT enzymes)
- NR has more published human clinical trial data — it was developed earlier and has undergone more systematic study. ChromaDex (which sells Tru Niagen) funded much of the early human NR research.
- NMN has more compelling rodent data (particularly from David Sinclair’s Harvard lab) and has been catching up in human trials since ~2020. Japan approved NMN as a food ingredient, spurring Japanese clinical research.
- Both demonstrably raise blood NAD+ levels in humans at appropriate doses (250-1000mg/day). This is not in dispute.
Human Clinical Trial Results
Where the evidence gets more complicated:
- A 2022 Nature Aging RCT (NMN, n=30, aged adults) showed blood NAD+ elevation but no significant change in metabolic markers (insulin sensitivity, body composition, muscle strength) vs placebo at 10 weeks
- Multiple NR trials show blood NAD+ elevation without consistent functional outcomes
- A 2023 Japanese RCT (NMN, n=108) showed improved muscle strength and gait speed in older adults — one of the more positive functional outcome trials
- Several small trials show improvements in specific biomarkers (blood pressure, cholesterol) but effect sizes are modest
The honest summary: NAD+ precursors reliably raise circulating NAD+ levels. Whether this translates to meaningful functional benefits in non-deficient human populations remains under active investigation. Larger, longer trials are underway.
Combining With Other Longevity Compounds
Researchers studying longevity often combine NAD+ precursors with compounds that reduce NAD+ consumption (CD38 inhibitors like apigenin/quercetin, PARP inhibitors) or compounds that activate sirtuins downstream (resveratrol, pterostilbene). The rationale is raising NAD+ while simultaneously reducing its wasteful consumption — though combination human data is very limited.
NMN’s FDA Legal Status: A Genuine Regulatory Reversal
NMN’s regulatory history is worth understanding directly, since it went through a real and consequential legal dispute rather than remaining a stable supplement ingredient throughout. In late 2022, the FDA withdrew NMN’s New Dietary Ingredient (NDI) status and excluded it from the legal definition of a dietary supplement, largely on the grounds that NMN had previously been investigated as a drug (under an Investigational New Drug application), which under FDA rules can preclude a substance from also being marketed as a supplement. This effectively banned NMN sales as a supplement in the U.S. and prompted the Natural Products Association (NPA) to file a lawsuit against the FDA in August 2024 seeking reversal. After nearly three years of dispute, the FDA reversed its position — confirming in September 2025, and further affirming in December 2025, that NMN can once again be legally marketed as a dietary supplement in the United States. This regulatory back-and-forth is a useful case study in how a substance’s legal supplement status can be genuinely unsettled and can change based on ongoing agency determinations and litigation, independent of the underlying biology.
NMN vs. NR: The Transport Mechanism Debate
A genuinely unresolved scientific question distinguishes NMN from NR (nicotinamide riboside): how each molecule actually gets into cells. NR is transported into cells relatively directly via established nucleoside transporters. NMN’s cellular entry mechanism has been more contested — some research has proposed a dedicated NMN transporter (Slc12a8, identified in a widely cited 2019 mouse study), while other research groups have argued NMN must first be converted extracellularly to NR (via the enzyme CD73) before cellular uptake, meaning NMN supplementation may functionally work by first becoming NR rather than entering cells as NMN directly. This mechanistic uncertainty matters because if NMN’s benefits depend on prior conversion to NR, then comparing NMN and NR supplementation as though they were fundamentally different delivery strategies may be a distinction without a difference at the cellular level — an open question the field has not fully settled.
Frequently Asked Questions
Is NMN currently legal to sell as a supplement in the U.S.?
Yes, as of the FDA’s September and December 2025 determinations, which reversed the agency’s 2022 exclusion of NMN from the dietary supplement definition following a lawsuit from the Natural Products Association.
Why was NMN banned as a supplement in the first place?
The FDA determined in 2022 that NMN’s prior investigation as a drug (under an IND application) precluded its supplement status under FDA rules — a technical regulatory determination unrelated to any new safety finding about the molecule itself.
Does NMN work through a different mechanism than NR?
This remains scientifically contested — some research proposes a dedicated NMN transporter, while other work suggests NMN must convert to NR before cellular uptake, meaning the two may be more mechanistically similar than commonly assumed.
Educational research content. NMN and NR are dietary supplements with an emerging but incomplete evidence base. Not medical advice.
